This is particularly important in cancer patients because, due to the reduced immunity, IFI may develop with only a few symptoms: refractory fever and increased markers of an ongoing infection (CRP and PCT), which do not respond to broad-spectrum antibiotic therapy [44,48,49,50,51]. The gene discussed is CRP; the disease is cancer.